To conduct an evidence-based technology assessment to determine whether tamoxifen and raloxifene as breast cancer risk-reduction strategies are appropriate for broad-based conventional use in clinical practice.
Tamoxifen and raloxifene.
Outcomes of interest include breast cancer incidence, breast cancer-specific survival, overall survival, and net health benefits.
A comprehensive, formal literature review was conducted for tamoxifen and raloxifene on the following topics : breast cancer risk reduction ;
tamoxifen side effects and toxicity, including endometrial cancer risk ;
tamoxifen influences on nonmalignant diseases, including coronary heart disease and osteoporosis ;
and decision making by women at risk for breast cancer.
Testimony was collected from invited experts and interested parties.
Values : More weight was given to publications that described randomized trials.
Benefits/Harms/Costs : The American Society of Clinical Oncology (ASCO) Working Group knowledges that a woman's decision regarding breast cancer risk-reduction strategies will depend on the importance and weight attributed to the information provided regarding both cancer and non-cancer-related risks.
For women with a defined 5-year projected risk of breast cancer of >= 1.66%, tamoxifen (at 20 mg/d for up to 5 years) may be offered to reduce their risk. (...)
Mots-clés Pascal : Tumeur maligne, Glande mammaire, Facteur risque, Tamoxifène, Antihormone, Antioestrogène, Raloxifène, Anticancéreux, Prévention, Chimioprophylaxie, Homme, Composé non stéroïde, Glande mammaire pathologie
Mots-clés Pascal anglais : Malignant tumor, Mammary gland, Risk factor, Tamoxifene, Antihormone, Antiestrogen, Raloxifene, Antineoplastic agent, Prevention, Chemoprophylaxis, Human, Non steroid compound, Mammary gland diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0309304
Code Inist : 002B02R02. Création : 16/11/1999.